|
1.
|
|
|
2.
|
|
9 p, 6.7 MB |
Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas
/
Bobillo, Sabela (Vall d'Hebron Institut d'Oncologia) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Escudero, Laura (Vall d'Hebron Institut d'Oncologia) ;
Mayor, Regina (Hospital Universitari Vall d'Hebron) ;
Raheja, Priyanka (Vall d'Hebron Institut d'Oncologia) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Rubio-Perez, Carlota (Vall d'Hebron Institut d'Oncologia) ;
Tazon-Vega, Barbara ;
Palacio, Carlos (Vall d'Hebron Institut d'Oncologia) ;
Carabia, Julia (Vall d'Hebron Institut d'Oncologia) ;
Jimenez, Isabel (Vall d'Hebron Institut d'Oncologia) ;
Nieto, Juan. C. (Vall d'Hebron Institut d'Oncologia) ;
Montoro, Julia (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Ricarte, Francisco (Hospital Universitari Vall d'Hebron) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron) ;
Simo, Marc (Hospital Universitari Vall d'Hebron) ;
Puigdefabregas, Lluis (Vall d'Hebron Institut d'Oncologia) ;
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier (Vall d'Hebron Institut d'Oncologia) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The levels of cell free circulating tumor DNA (ctDNA) in plasma correlate with treatment response and outcome in systemic lymphomas. Notably, in brain tumors, the levels of ctDNA in the cerebrospinal fluid (CSF) are higher than in plasma. [...]
2020 -  10.3324/haematol.2019.241208
Haematologica, Vol. 106 (february 2020) , p. 513-521
|
|
|
3.
|
|
13 p, 3.3 MB |
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition
/
Jiménez, Isabel (Vall d'Hebron Institut d'Oncologia) ;
Carabia, Júlia (Vall d'Hebron Institut d'Oncologia) ;
Bobillo, Sabela (Vall d'Hebron Institut d'Oncologia) ;
Palacio, Carles (Vall d'Hebron Institut d'Oncologia) ;
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ;
Pagès, Carlota (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Nieto, Juan C. (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron) ;
Martinez-Ricarte, Fran (Hospital Universitari Vall d'Hebron) ;
Escoda, Lourdes (Hospital Universitari Joan XXIII de Tarragona) ;
Perla, Cristóbal (Hospital Universitari Joan XXIII de Tarragona) ;
Céspedes Torrez, Dennis H. (Hospital Universitari Joan XXIII de Tarragona) ;
Boix, Joan (Vall d'Hebron Institut d'Oncologia) ;
Purroy, Noelia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Puigdefàbregas, Lluís (Vall d'Hebron Institut d'Oncologia) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier (Vall d'Hebron Institut d'Oncologia) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia)
Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but clinical responses to its inhibition using ibrutinib have been brief. [...]
2020 - 10.1007/s11060-020-03580-y
Journal of Neuro-Oncology, Vol. 149 (july 2020) , p. 13-25
|
|
|
4.
|
|
30 p, 7.5 MB |
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
/
De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ;
Sammut, S.J. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Ross, E.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Bashford-Rogers, R. (Department of Medicine. University of Cambridge) ;
Greenstein, E. (Weizmann Institute of Science (Israel). Department of Immunology) ;
Markus, H. (Mayo Clinic Center for Individualized Medicine) ;
Morganella, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Teng, Y. (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ;
Maruvka, Y. (Massachusetts General Hospital) ;
Pereira, B. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Rueda, O.M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Chin, S.F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Contente-Cuomo, T. (Mayo Clinic Center for Individualized Medicine) ;
Mayor, R. (Centro de Investigación Biomédica en Red de Cáncer) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Ali, H.R. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Cope, W. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Tiezzi, D. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Dariush, A. (Institute of Astronomy. University of Cambridge) ;
Dias Amarante, T. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Reshef, D. (Weizmann Institute of Science (Israel). Department of Immunology) ;
Ciriaco, 0000-0002-1151-554X (Hospital Universitari Vall d'Hebron) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Vassiliou, G. (Wellcome Trust/MRC Cambridge Stem Cell Institute) ;
Getz, G. (Massachusetts General Hospital) ;
Nik-Zainal, S. (Department of Medical Genetics. The Clinical School. University of Cambridge) ;
Murtaza, M. (Mayo Clinic Center for Individualized Medicine) ;
Friedman, N. (Weizmann Institute of Science (Israel). Department of Immunology) ;
Markowetz, F. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Caldas, C. (Cancer Research UK Cambridge Cancer Centre (Regne Unit)) ;
Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 - 10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10
|
|
|
5.
|
|
11 p, 3.2 MB |
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy
/
Pascual-García, Mónica (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bonfill-Teixidor, Ester (Vall d'Hebron Institut d'Oncologia) ;
Planas-Rigol, Ester (Vall d'Hebron Institut d'Oncologia) ;
Rubio-Perez, Carlota (Vall d'Hebron Institut d'Oncologia) ;
Iurlaro, Raffaella (Vall d'Hebron Institut d'Oncologia) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Cuartas, Isabel (Vall d'Hebron Institut d'Oncologia) ;
Sala-Hojman, Ada (Vall d'Hebron Institut d'Oncologia) ;
Escudero, Laura (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Ricarte, Fran (Universitat Autònoma de Barcelona) ;
Huber-Ruano, Isabel (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Pedrosa, Leire (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Marques, Carlota (Centro Nacional de Investigaciones Oncológicas) ;
Braña, Irene (Vall d'Hebron Institut d'Oncologia) ;
Garralda, Elena (Vall d'Hebron Institut d'Oncologia) ;
Vieito, María (Vall d'Hebron Institut d'Oncologia) ;
Squatrito, Juan (Centro Nacional de Investigaciones Oncológicas) ;
Pineda, Estela (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Graus Ribas, Francesc (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Espejo, Carmen (Universitat Autònoma de Barcelona) ;
Sahuquillo Barris, Juan (Universitat Autònoma de Barcelona) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats)
Cancer response to immunotherapy depends on the infiltration of CD8 T cells and the presence of tumor-associated macrophages within tumors. Still, little is known about the determinants of these factors. [...]
2019 - 10.1038/s41467-019-10369-9
Nature communications, Vol. 10 Núm. 1 (january 2019) , p. 2416
|
|
|
6.
|
|
14 p, 4.6 MB |
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
/
De Mattos-Arruda, Leticia (Memorial Sloan Kettering Cancer Center) ;
Ng, Charlotte K. Y. (Department of Biomedicine, University of Basel, Basel, Switzerland) ;
Piscuoglio, Salvatore (Institute of Pathology, University Hospital Basel) ;
Gonzalez-Cao, Maria (Grup Quirónsalud (Barcelona, Catalunya)) ;
Lim, Raymond S. (Memorial Sloan Kettering Cancer Center) ;
De Filippo, Maria R. (Memorial Sloan Kettering Cancer Center) ;
Fusco, Nicola (Memorial Sloan Kettering Cancer Center) ;
Schultheis, Anne M. (Memorial Sloan Kettering Cancer Center) ;
Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Macedo, Gabriel S. (Memorial Sloan Kettering Cancer Center) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Gomez, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Teixidó, Cristina (Grup Quirónsalud (Barcelona, Catalunya)) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Tresserra Casas, Francesc (Grup Quirónsalud (Barcelona, Catalunya)) ;
Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ;
Cortés, Javier (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ;
Reis-Filho, Jorge S. (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center)
Brain metastases constitute a challenge in the management of patients with HER2-positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to define the repertoire of mutations private to or enriched for in HER2-positive brain metastases. [...]
2018 - 10.18632/oncotarget.25041
Oncotarget, Vol. 9 (april 2018) , p. 20617-20630
|
|
|
7.
|
|
8 p, 500.8 KB |
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
/
Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ;
Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ;
Desaiah, Durisala (Eli Lilly and Company (USA)) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Braña, Irene (Hospital Universitari Vall d'Hebron) ;
Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ;
Miles, Colin (Eli Lilly and Company (United Kingdom)) ;
Lahn, Michael M (Eli Lilly and Company (USA)) ;
Mitchell, Malcolm I (Eli Lilly and Company (USA)) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303
|
|
|
8.
|
|
12 p, 2.2 MB |
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
/
De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ;
Bottai, Giulia (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Di Tommaso, Luca (IRCCS Humanitas Clinical and Research Institute (Itàlia)) ;
Giovannetti, Elisa (University of Pisa. Cancer Pharmacology Laboratory. AIRC Start-Up Unit (Italy)) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Losurdo, Agnese (IRCCS Humanitas Clinical and Research Institute (Itàlia). Division of Oncology and Hematology) ;
Pérez-Garcia, José (Vall d'Hebron Institut d'Oncologia) ;
Masci, Giovanna (IRCCS Humanitas Clinical and Research Institute (Itàlia). Division of Oncology and Hematology) ;
Corsi, Fabio (University of Milan. Deparment of Clinical and Biomedical Sciences "Luigi Sacco" (Italy)) ;
Cortés, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ;
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ;
Calin, George A. (The University of Texas MD Anderson Cancer Center (USA)) ;
Santarpia, Libero (Oncology Experimental Therapeutics Unit. IRCCS Humanitas Clinical and Research Institute (Italy)) ;
Universitat Autònoma de Barcelona
Patients with primary HER2-positive breast cancer benefit from HER2-targeted therapies. Nevertheless, a significant proportion of these patients die of disease progression due to mechanisms of drug resistance. [...]
2015 - 10.18632/oncotarget.5495
Oncotarget, Vol. 6, Num. 35 (October 2015) , p. 37269-37280
|
|
|
9.
|
|
14 p, 1.9 MB |
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
/
Rodón, Jordi (Hospital Universitari Vall d'Hebron) ;
Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ;
Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Azaro, Analía (Hospital Universitari Vall d'Hebron) ;
Calvo, Emiliano (Centro Integral Oncológico Clara Campal-HM CIOCC (Madrid, Espanya)) ;
Seoane Suárez, Joan (Hospital Universitari Vall d'Hebron) ;
Braña, Irene (Hospital Universitari Vall d'Hebron) ;
Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ;
Gueorguieva, Ivelina (Eli Lilly and Company) ;
Cleverly, Ann (Eli Lilly and Company) ;
Pillay, N. Sokalingum (Eli Lilly and Company) ;
Desaiah, Durisala (Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company) ;
Paz-Ares, Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ;
Blakeley, Jaishri (Johns Hopkins University) ;
Lahn, Michael M. (Eli Lilly and Company) ;
Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370
|
|
|
10.
|
|
11 p, 1.8 MB |
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
/
Annibali, Daniela (University of California) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Favuzzi, Emilia (Università La Sapienza) ;
Jauset, Toni (Universitat Autònoma de Barcelona) ;
Serrano, Erika (Universitat Autònoma de Barcelona) ;
Cuartas, Isabel (Universitat Autònoma de Barcelona) ;
Redondo Campos, Sara (Universitat Autònoma de Barcelona) ;
Folch, Gerard (Universitat Autònoma de Barcelona) ;
Gonzàlez Juncà, Alba (Universitat Autònoma de Barcelona) ;
Sodir, Nicole M. (University of Cambridge) ;
Massó Vallés, Daniel (Universitat Autònoma de Barcelona) ;
Beaulieu, Marie-Eve (Universitat Autònoma de Barcelona) ;
Swigart, Lamorna B. (University of California) ;
Mc Gee, Margaret M. (University College Dublin) ;
Somma, Maria Patrizia (Università La Sapienza) ;
Nasi, Sergio (Università La Sapienza) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats) ;
Evan, Gerard I. (University of Cambridge) ;
Soucek, Laura (Universitat Autònoma de Barcelona)
Gliomas are the most common primary tumours affecting the adult central nervous system and respond poorly to standard therapy. Myc is causally implicated in most human tumours and the majority of glioblastomas have elevated Myc levels. [...]
2014 - 10.1038/ncomms5632
Nature communications, Vol. 5 (August 2014) , art. 4632
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
